Nuh N. Rahbari
A5058193717- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Cardiovascular Disease and Adiposity
- Colorectal Cancer Surgical Treatments
- Pancreatitis Pathology and Treatment
- Organ Transplantation Techniques and Outcomes
- Cancer Immunotherapy and Biomarkers
- Liver Disease Diagnosis and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Gallbladder and Bile Duct Disorders
- Adipokines, Inflammation, and Metabolic Diseases
- Gastric Cancer Management and Outcomes
- Liver Disease and Transplantation
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Immune Cell Function and Interaction
- Angiogenesis and VEGF in Cancer
- Cancer Genomics and Diagnostics
- Fibroblast Growth Factor Research
- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
- Colorectal Cancer Screening and Detection
Heidelberg University
2015-2025
University Hospital Heidelberg
2014-2025
University Medical Centre Mannheim
2018-2025
University Hospital Ulm
2023-2025
Chirurgische Universitätsklinik Heidelberg
2008-2023
German Cancer Research Center
2011-2023
Medizinische Fakultät Mannheim
2021-2023
University of Mannheim
2023
TU Dresden
2014-2022
University Hospital Carl Gustav Carus
2013-2021
Abstract Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification patients optimal response to therapy unmet need 6,7 Here we report the progressive accumulation exhausted, unconventionally activated CD8 + PD1 T cells in NASH-affected livers. In preclinical models NASH-induced therapeutic immunotherapy targeted at programmed...
It remains unclear how obesity worsens treatment outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). In normal pancreas, promotes inflammation and fibrosis. We found mouse models of PDAC that also desmoplasia associated accelerated tumor growth impaired delivery/efficacy chemotherapeutics through reduced perfusion. Genetic pharmacologic inhibition angiotensin-II type-1 receptor reverses obesity-augmented improves response to chemotherapy. Augmented activation stellate cells...
Sepsis is a frequently fatal condition characterized by an uncontrolled and harmful host reaction to microbial infection. Despite the prevalence severity of sepsis, we lack fundamental grasp its pathophysiology. Here report that cytokine interleukin-3 (IL-3) potentiates inflammation in sepsis. Using mouse model abdominal showed innate response activator B cells produce IL-3, which induces myelopoiesis Ly-6C(high) monocytes neutrophils fuels storm. IL-3 deficiency protects mice against In...
Abstract Purpose: Tumor infiltrating T lymphocytes in colorectal cancer (CRC) have prognostic impact, but the role of natural killer (NK) cells CRC tissue is unclear. The contribution intratumoral cytokines and chemokines shaping composition inflammatory lymphocytic infiltrate also Experimental Design: In this study, localization densities NK within primary CRC, liver metastases, adenomas, normal tissues were analyzed on whole sections from 112 patients. a subset these patients, most...
Anti-VEGF therapy enhances mechanical barriers to in colorectal cancer liver metastases by increasing hyaluronan deposition.
Abstract The prognosis of colorectal cancer is closely linked to the occurrence distant metastases. Systemic dissemination most likely caused by circulating tumor cells (CTC). Despite fundamental role CTC within metastatic cascade, technical obstacles have so far prevented detailed genomic and, in particular, phenotypic analyses CTC, which may provide molecular targets delay or prevent We show here a analysis single cancer–derived array comparative hybridization (aCGH), mutational profiling,...
•Baseline serum AFP ≥100 ng/ml and CRP ≥1 mg/dl were independently associated with worse OS in ICB-treated patients HCC.•A score based on these two variables predicts disease control rate overall survival HCC.•The was validated an independent cohort of HCC.•In sorafenib-treated HCC, the prognostic for but not predictive rate. Background & AimsImmunotherapy atezolizumab plus bevacizumab represents new standard care systemic front-line treatment hepatocellular carcinoma (HCC). However,...
Anti-vascular endothelial growth factor (VEGF) therapy has failed to improve survival in patients with breast cancer (BC). Potential mechanisms of resistance anti-VEGF include the up-regulation alternative angiogenic and proinflammatory factors. Obesity is associated hypoxic adipose tissues, including those breast, resulting increased production some aforementioned Hence, we hypothesized that obesity could contribute therapy's lack efficacy. We found BC harbored systemic concentrations...
The progression of non-alcoholic steatohepatitis (NASH) to fibrosis and hepatocellular carcinoma (HCC) is aggravated by auto-aggressive T cells. gut-liver axis contributes NASH, but the mechanisms involved consequences for NASH-induced liver cancer remain unknown. We investigated role gastrointestinal B cells in development HCC.
Abstract Background Posthepatectomy liver failure (PHLF) contributes significantly to morbidity and mortality after surgery. Standardized assessment of preoperative function is crucial identify patients at risk. These European consensus guidelines provide guidance for patient assessment. Methods A modified Delphi approach was used achieve consensus. The expert panel consisted hepatobiliary surgeons, radiologists, nuclear medicine specialists, hepatologists. guideline process supervised by a...
Spontaneous antitumor T cell responses in cancer patients are strongly controlled by Tregs, and increased numbers of tumor-infiltrating Tregs correlate with reduced survival. However, the tumor antigens recognized impact these cells on tumor-specific have not been systematically characterized. Here we used a broad panel long synthetic peptides defined normal tissue to exploit newly developed method identify compare ex vivo antigen specificities those effector/memory peripheral blood...
Circulating tumour cells (CTC) in the blood have been accepted as a prognostic marker patients with metastatic colorectal cancer (CRC). Only limited data exist on impact of CTC early stage CRC using standardised detection assays. The aim this study was to elucidate role non-metastatic CRC. A total 287 potentially curable were enrolled, including 239 UICC I–III. measured CellSearch system preoperatively and postoperative days 3 7. complete patient group (UICC I–IV) cohort I–III) analysed...